BIGESPAS Ltd, is a UK based private company established in 2020 to run an anti-Alzheimer drug development project. The company holds US 12 084 440 B2 patent which secures a know-how related to the discovered polymorph DMB-I of Latrepirdine.
In 2023 BIGESPAS Ltd has started Phase II trial on its drug product Dimebon® DMB-I based on
successful data received on previous animal studies stage.
In 2025 The Company completed the 28 weeks
Phase II clinical trial evaluating the safety and efficacy of DMB-I in 135 patients with mild-to-moderate Alzheimer’s disease. The outcome is a substantial cognitive improvement over placebo (i.e., Memantine), with measurable patient response observed from Week 12 and sustained throughout the treatment period.